2020
Efficacy of Tafamidis in Transthyretin Amyloid Cardiomyopathy in the ATTR-ACT Trial
Berk J, Damy T, Drachman B, Elliott P, Gottlieb S, Grogan M, Gundapaneni B, Hanna M, Hoffman J, Hummel S, Judge D, Lenihan D, Merlini G, Patterson T, Rapezzi C, Schwartz J, Shah S, Sultan M, Velazquez E, Cruz M, Witteles R. Efficacy of Tafamidis in Transthyretin Amyloid Cardiomyopathy in the ATTR-ACT Trial. Heart & Lung 2020, 49: 209-210. DOI: 10.1016/j.hrtlng.2020.02.009.Peer-Reviewed Original ResearchEfficacy of tafamidisSix-minute walk distanceATTR-CMCause mortalityQuality of lifeWalk distanceHeart failureKansas City Cardiomyopathy Questionnaire overall scorePre-specified sensitivity analysisSix-minute walk test distanceTransthyretin Cardiomyopathy Clinical TrialHard cardiovascular endpointsFirst-line therapyKey secondary endpointPrimary efficacy analysisTransthyretin amyloid cardiomyopathyOverall scoreMechanical assist devicesClinical laboratory testsNovel study designNYHA classTafamidis groupPlacebo groupSecondary endpointsAdverse events
2018
Impaired Recovery of Left Ventricular Function in Patients With Cardiomyopathy and Left Bundle Branch Block
Sze E, Samad Z, Dunning A, Campbell KB, Loring Z, Atwater BD, Chiswell K, Kisslo JA, Velazquez EJ, Daubert JP. Impaired Recovery of Left Ventricular Function in Patients With Cardiomyopathy and Left Bundle Branch Block. Journal Of The American College Of Cardiology 2018, 71: 306-317. PMID: 29348023, PMCID: PMC8352572, DOI: 10.1016/j.jacc.2017.11.020.Peer-Reviewed Original ResearchConceptsGuideline-directed medical therapyLeft bundle branch blockCardiac resynchronization therapyWide QRS durationBundle branch blockQRS durationLVEF improvementQRS morphologyReduced LVEFBranch blockLeft ventricular ejection fraction improvementVentricular ejection fraction improvementEjection fraction improvementMean LVEF improvementNarrow QRS durationSevere valve diseaseFirst-line therapyHeart failure hospitalizationLeft ventricular functionVentricular assist deviceBaseline electrocardiographyFailure hospitalizationCombined endpointSignificant comorbiditiesResynchronization therapy
2016
Platypnea-Orthodeoxia Syndrome: To Shunt or Not to Shunt, That is the Question
Klein MR, Kiefer TL, Velazquez EJ. Platypnea-Orthodeoxia Syndrome: To Shunt or Not to Shunt, That is the Question. Texas Heart Institute Journal 2016, 43: 264-6. PMID: 27303248, PMCID: PMC4894711, DOI: 10.14503/thij-15-5280.Peer-Reviewed Original ResearchConceptsRight atrial pressurePatent foramenAtrial pressureLow right atrial pressureRight-sided heart catheterizationFirst-line therapyPlatypnea-orthodeoxia syndromePercutaneous patent foramenPulmonary arteriovenous malformationsUpright positionCardiac causesHeart catheterizationTransient hypoxemiaTransthoracic echocardiogramTransthoracic echocardiographyLeft shuntingSyncopal episodesPercutaneous closureTransesophageal echocardiogramEmergency departmentOxygen supplementationIntracardiac shuntingArteriovenous malformationsChest radiographsOxygen saturation